Astellas reports first Xtandi sales

Medivation Inc. (NASDAQ:MDVN) recorded $14 million in U.S. sales of prostate cancer drug Xtandi enzalutamide since the drug's launch in September, according to fiscal 1H13 earnings reported by Astella...